<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>937</td>
<td>Highlights of This Issue</td>
<td></td>
</tr>
<tr>
<td>939</td>
<td>CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341</td>
<td>Beverly A. Teicher and Kenneth C. Anderson</td>
</tr>
<tr>
<td>944</td>
<td>Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better</td>
<td>Roxana S. Dronca and Haidong Dong</td>
</tr>
<tr>
<td>947</td>
<td>Moving from Evaluation to Value in Cancer Care</td>
<td>Richard L. Schilsky</td>
</tr>
<tr>
<td>950</td>
<td>FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease</td>
<td>Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F. Zirkelbach, Liang Zhao, Julie Bullock, Nitin Mehrotra, Pedro Del Valle, Haleh Saber, Christopher Sheth, Brenda Gehrze, Robert Justice, Ann Farrell, and Richard Pazdur</td>
</tr>
<tr>
<td>955</td>
<td>Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer</td>
<td>Rebecca A. Preeva, Robert L. Coleman, Adrian L. Harris, and Anil K. Sood</td>
</tr>
<tr>
<td>962</td>
<td>Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis</td>
<td>Hae-Yun Jung, Laurent Fattet, and Jing Yang</td>
</tr>
<tr>
<td>969</td>
<td>Zebrafish: A New Companion for Translational Research in Oncology</td>
<td>Jorge Barriuso, Raghavendra Nagaraju, and Adam Hurlstone</td>
</tr>
<tr>
<td>995</td>
<td>CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb⁺ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment</td>
<td>Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gramlich, Maryann Gallagher, Priti Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer, Noah Goodman, Susan Domchek, Kerrih Gogineni, Mark Rosen, Kevin Fox, and Peter O’Dwyer</td>
</tr>
</tbody>
</table>
Table of Contents

1019 A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins, Sadik H. Kassim, Thai I.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James C. Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi-Chia R. Lee, Yong F. Li, Mona El-Gamil, and Steven A. Rosenberg

1028 Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg, David G. McFadden, Edwin L. Palmer, Gilbert H. Daniels, and Lori J. Wirth

1036 Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors
Alberto F. Sobrero, Alessandro Pastorino, Daniel J. Sargent, and Paolo Bruzzi
See related commentary, p. 947

1044 A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, and Anthony B. El-Khoueiry

PERSONALIZED MEDICINE AND IMAGING

1052 Nottingham Clinico-Pathological Response Index (NPIR) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

1063 Longitudinal Noninvasive Imaging of Progestosterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy
Szanem Ruby Chan, Amy M. Fowler, Julie A. Allen, Dong Zhou, Carmen S. Dence, Terry L. Sharp, Nicole M. Fettig, Farrokh Dehdashi, and John A. Katzenellenbogen

CANCER THERAPY: PRECLINICAL

1071 Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Toni K. Choueiri, David J. Figueroa, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, and Robert J. Motzer

1078 Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)
Stephanie M. Cushman, Chen Jiang, Ace I. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouroos Owzar, Herbert I. Hurwitz, and Andrew B. Nixon

1087 Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
Pierre Laurenzi-Puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos, Philippe Nizard, Karla Perez-Toralla, Rachel Rowell, Jeff Olson, Preethi Srinivasan, Delphine Le Corre, They Hor, Zakaria El Harrak, Xinyu Li, Darren R. Link, Olivier Bouché, Jean-François Emile, Bruno Landi, Valérie Boige, J. Brian Hutchison, and Valerie Tal

1098 Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

1106 Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Kristan Meetze, Sylvie Vincent, Steven Tyler, Elizabeth K. Maza, Andrea R. Delpero, Steve Bottega, Donna McIntosh, Richard Nicoletti, William M. Winston, Sally Weiler, Bin Feng, Jero Gryuis, and Zhigang Weng

CANCER THERAPY: PRECLINICAL

1115 The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Sara M. Mangsbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furebring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H. Tottman, and Peter Ellmark
See related commentary, p. 944
BIOLOGY OF HUMAN TUMORS

1196 Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Andrew Feber, Manit Arya, Patricia de Winter, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Matthias Lechner, Alex Freeman, Charles Jameson, Asif Muneer, Stephan Beck, and John D. Kelly

1207 A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Kristine Kleivi Sahilberg, Giulia Bottai, Bjørn Naume, Barbara Burwinkel, George A. Calin, Anne-Lise Berresen-Dale, and Libero Santarpia

1215 Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Raphael Marechal, Jean-Baptiste Batch, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Svreek, Jérôme Cros, Armelle Bardier-Dupas, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Treut, Jean-Christophe Vaillant, Alain Sauvanet, Thierry André, Isabelle Salmon, Jacques Deviere, Jean-François Emile, and Jean-Luc Van Laethem

1225 Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Xin Zhang, Xiaoyun Yang, Yanli Zhang, Xinfeng Liu, Guixi Zheng, Yongmei Yang, Lili Wang, Lutao Du, and Chuanxin Wang
ABOUT THE COVER

The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.